CE1226

Phase 3Biologic

CSL Behring

CE1226 is one of 8 biologic programs targeting Double-blind. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Double-BlindNot yet recruiting

Double-BlindPhase 3

Not yet recruiting

Competition

Competitive Landscape

10 competitors in Double-Blind

#DrugCompanyPhaseTrials

Olumiant

Eli Lilly

Phase 3

1 2

Albenza

IImpax Laboratories, LLC

Phase 3

1 3

CE1226

CSL Behring

Phase 3

1 4

Everolimus and Lonafarnib

BBoston Children's Hospital

Phase 3

1 5

Inosine Pranobex

NNewport Pharmaceuticals International

Preclinical

2 6

PORT-77

PPortal Therapeutics, Inc.

Phase 1

1 7

Western Therapy

JJiangxi Qingfeng Pharmaceutical Co. Ltd.

Preclinical

1 8

Interferon Alfa-N3

IInterferon Sciences

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2033

Post-ApprovalNot yet recruiting

Double-Blind

NCT07326592

Clinical

Trials by Indication[1]

Double-blind1 trial

Phase 4, Double-blind Study Evaluating the Response on Computed Tomography (CT) Lung Density Decline Rates of Respreeza / Zemaira Weekly for 3 Years in Adults With alpha1 Antitrypsin Deficiency (AATD)

Not yet recruiting· CSL Behring logo

CSL Behring·Phase 4·NCT07326592·270 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CE1226. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CE1226 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CE1226. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — CSL Behring company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: CSL Behring

CE1226

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2033

Trials by Indication[1]

Double-blind1 trial

References

Drug Info

Quick Facts

Related News